The launch announcement was made by Cyclica’s president and CEO, Naheed Kurji, at Collision Conference in Toronto. Biotechnology company Cyclica has developed a drug discovery platform called Ligand Design which aims to help pharmaceutical companies create new drug-like compounds using a genetic algorithm and AI-based POEM technology. The platform, named after the Greek word for “life,” is designed to identify molecules that are likely to be useful in treating diseases such as cancer, diabetes, Alzheimer’s disease, Parkinson’s disease or HIV.
Biotechnology company Cyclica has developed a drug discovery platform called Ligand Design which aims to help pharmaceutical companies create new drug-like compounds using a genetic algorithm and AI-based POEM technology. The platform, named after the Greek word for “life,” is designed to identify molecules that are likely to be useful in treating diseases such as cancer, diabetes, Alzheimer’s disease, Parkinson’s disease or HIV.